SRTS

+ Watchlist + Portfolio

Sensus Healthcare, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.95
52-Week Range: $2.66 – $5.49
Market Cap: $49.06M
P/E (TTM): —
EPS (TTM): -0.94
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.33
PEG Ratio: —
Return on Equity: -34.83%
Return on Assets: -16.55%
Gross Margin: 36.39%
Operating Margin: -138.87%
Profit Margin: -88.45%
Current Ratio: 8.71
Debt/Equity: 0.01
Total Debt: $343.00K
Free Cash Flow: $-2.08M
Revenue Growth: -68.70%
Earnings Growth: —
Enterprise Value: $34.21M

SRTS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$44.53M	$24.41M	$41.81M	$27.48M
Cost of Revenue	$14.90M	$10.35M	$17.38M	$15.62M
Gross Profit	$29.63M	$14.06M	$24.43M	$11.87M
Research & Development	$3.46M	$3.68M	$4.22M	$7.78M
Selling, General & Admin	$11.34M	$10.76M	$12.13M	$14.40M
Operating Expenses	$14.80M	$14.44M	$16.34M	$22.17M
Operating Income	$14.83M	-$382.00K	$8.09M	-$10.31M
EBITDA	$15.34M	$79.00K	$8.52M	-$9.68M
Pretax Income	$27.99M	$652.00K	$9.02M	-$9.62M
Income Tax	$3.75M	$167.00K	$2.38M	-$1.91M
Net Income	$24.24M	$485.00K	$6.65M	-$7.72M
Diluted EPS	1.46	0.03	0.41	-0.47
Diluted Shares	16.62M	16.27M	16.36M	16.33M

SRTS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$25.52M	$23.15M	$22.06M	$22.08M
Receivables	$17.30M	$10.64M	$19.73M	$6.04M
Inventory	$3.50M	$11.86M	$10.10M	$14.56M
Current Assets	$53.24M	$49.53M	$56.74M	$45.89M
Total Assets	$56.73M	$53.71M	$62.16M	$53.04M
Current Liabilities	$7.70M	$4.21M	$5.88M	$4.72M
Total Debt	$1.02M	$783.00K	$602.00K	$471.00K
Total Liabilities	$8.67M	$4.87M	$6.34M	$4.94M
Retained Earnings	$6.30M	$6.79M	$13.43M	$5.71M
Shareholders' Equity	$48.07M	$48.84M	$55.83M	$48.10M
Working Capital	$45.54M	$45.32M	$50.85M	$41.17M

SRTS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.41M	-$2.15M	-$831.00K	$528.00K
Capital Expenditure	-$159.00K	-$229.00K	-$276.00K	-$196.00K
Free Cash Flow	-$1.57M	-$2.37M	-$1.11M	$332.00K
Depreciation & Amortisation	$509.00K	$461.00K	$432.00K	$626.00K
Stock-Based Compensation	$187.00K	$328.00K	$323.00K	$295.00K
Investing Cash Flow	$14.84M	-$187.00K	-$276.00K	-$196.00K
Financing Cash Flow	-$2.43M	-$40.00K	$15.00K	-$305.00K
Share Repurchases	-$3.00M	-$27.00K	$0.00	-$300.00K
Net Change in Cash	$11.00M	-$2.37M	-$1.09M	$27.00K

SRTS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$8.34M	$7.32M	$6.88M	$4.94M	$3.39M	$2.29M
Cost of Revenue	$3.99M	$4.41M	$4.17M	$3.04M	$2.40M	$1.52M
Gross Profit	$4.35M	$2.90M	$2.71M	$1.90M	$991.00K	$769.00K
Research & Development	$2.61M	$1.47M	$1.82M	$1.88M	$1.59M	$1.11M
Selling, General & Admin	$4.39M	$3.38M	$3.46M	$3.16M	$3.76M	$2.84M
Operating Expenses	$7.00M	$4.85M	$5.28M	$5.04M	$5.35M	$3.95M
Operating Income	-$2.65M	-$1.94M	-$2.57M	-$3.15M	-$4.36M	-$3.18M
EBITDA	-$2.50M	-$1.78M	-$2.41M	-$2.98M	-$4.20M	-$3.03M
Pretax Income	-$2.46M	-$1.76M	-$2.41M	-$2.99M	-$4.23M	-$3.06M
Income Tax	$110.00K	-$723.00K	-$1.47M	$174.00K	-$1.61M	$5.69M
Net Income	-$2.57M	-$1.04M	-$943.00K	-$3.17M	-$2.63M	-$8.75M
Diluted EPS	-0.16	-0.06	-0.06	-0.19	-0.16	-0.53
Diluted Shares	16.34M	16.32M	16.32M	16.33M	16.46M	16.46M

SRTS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$19.07M	$22.16M	$24.45M	$22.08M	$18.33M	$15.19M
Receivables	$18.02M	$12.62M	$9.34M	$6.04M	$3.58M	$1.68M
Inventory	$9.92M	$12.40M	$13.04M	$14.56M	$16.50M	$18.46M
Current Assets	$54.20M	$52.22M	$50.20M	$45.89M	$42.59M	$37.68M
Total Assets	$60.21M	$58.85M	$58.30M	$53.04M	$51.55M	$41.26M
Current Liabilities	$6.72M	$6.41M	$6.80M	$4.72M	$5.86M	$4.33M
Total Debt	$654.00K	$595.00K	$534.00K	$471.00K	$408.00K	$343.00K
Total Liabilities	$7.18M	$6.79M	$7.10M	$4.94M	$6.00M	$4.40M
Retained Earnings	$10.86M	$9.82M	$8.88M	$5.71M	$3.09M	-$5.66M
Shareholders' Equity	$53.03M	$52.06M	$51.19M	$48.10M	$45.54M	$36.86M
Working Capital	$47.47M	$45.81M	$43.40M	$41.17M	$36.73M	$33.35M

SRTS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.68M	$3.12M	$2.29M	-$2.21M	-$3.75M	-$3.13M
Capital Expenditure	-$7.00K	-$27.00K	-$4.00K	-$158.00K	-$3.00K	-$8.00K
Free Cash Flow	-$2.68M	$3.09M	$2.29M	-$2.37M	-$3.76M	-$3.14M
Depreciation & Amortisation	$145.00K	$158.00K	$159.00K	$164.00K	$158.00K	$147.00K
Stock-Based Compensation	$79.00K	$67.00K	$73.00K	$76.00K	$70.00K	$70.00K
Investing Cash Flow	-$7.00K	-$27.00K	-$4.00K	-$158.00K	-$3.00K	-$8.00K
Financing Cash Flow	-$300.00K	$0.00	$0.00	-$5.00K	$0.00	$0.00
Share Repurchases	-$300.00K	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$2.98M	$3.09M	$2.29M	-$2.37M	-$3.76M	-$3.14M

Market Snapshot

About

Sensus Healthcare, Inc. is a medical device company that manufactures and sells radiation therapy devices. The company focuses on non-invasive treatments for both oncological and non-oncological skin conditions using superficial radiation therapy (SRT). Its products are used by dermatologists, radiation oncologists, and other healthcare providers to treat skin cancer and keloids.